Gritstone Bio Inc (GRTS)
0.9627
+0.09
(+10.66%)
USD |
NASDAQ |
May 03, 16:00
0.9633
0.00 (0.00%)
After-Hours: 20:00
Gritstone Bio Cash from Financing (TTM): 25.12M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 25.12M |
September 30, 2023 | 73.76M |
June 30, 2023 | 93.37M |
March 31, 2023 | 92.66M |
December 31, 2022 | 83.10M |
September 30, 2022 | 51.61M |
June 30, 2022 | 89.01M |
March 31, 2022 | 90.45M |
December 31, 2021 | 108.76M |
September 30, 2021 | 201.32M |
June 30, 2021 | 144.61M |
Date | Value |
---|---|
March 31, 2021 | 147.54M |
December 31, 2020 | 135.80M |
September 30, 2020 | 14.64M |
June 30, 2020 | 14.85M |
March 31, 2020 | 79.96M |
December 31, 2019 | 74.40M |
September 30, 2019 | 160.83M |
June 30, 2019 | 172.08M |
March 31, 2019 | 110.52M |
December 31, 2018 | 110.44M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
14.64M
Minimum
Sep 2020
201.32M
Maximum
Sep 2021
97.57M
Average
90.45M
Median
Mar 2022
Cash from Financing (TTM) Benchmarks
Precision BioSciences Inc | 5.387M |
Humacyte Inc | 4.507M |
Verastem Inc | 134.19M |
BioVie Inc | 15.36M |
Adial Pharmaceuticals Inc | 4.132M |